Dr. Hatou ＆ Dr. Sayano presented recent research progress in the 20th Congress of the Japanese Society for Regenerative Medicine.

Tokyo (March 11, 2021)-, Dr. Hatou, founder & CEO of Cellusion Inc., and Dr. Sayano, chief researcher, presented recent research progress in the 20th Congress of the Japanese Society for Regenerative Medicine held online from March. 11th to 13th. The presentation numbers are SY-48-4, O-08-3, and P-11-03.

With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.

Details on the 20th Congress of the Japanese Society for Regenerative Medicine, please see below. https://site2.convention.co.jp/20jsrm/en/index.html

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/